Regardless of what news is being anticipated out of Mesoblast, your investment here will be amply rewarded, in time, and that time is drawing relatively near.
"Results may not be reported until early 2018" but I would imagine they might report based on the 90-day interim results, if deemed important. Remember, Hardy said PMDA would approve based on "safety and a "tendency" of effectiveness". There is the chance that patients responding early to treatment (in sufficient numbers) may be enough for them to approve early. Others here agree or disagree? We have the other trials ongoing, we can't languish until 2018.
We are breaking out on the two-hour, daily, and have a nice tall white (or green) candle on the weekly. The monthly candle so far in June is up .19 and challenging the upper resistance of the downtrend channel as I write this. We have risen out of the symmetrical triangle, that bounded our stock for two and a half months, since around March 7th. With more follow through, we'll break that long term downtrend. The Stanford study and new article on Seeking Alpha together with some possible short covering today, is certainly helping investors here. So much to like about being invested here, good charts are now our friend.
I did go there Jerry, they're not threatened by, but embrace the stem success of Sanbio using stem cells to demonstrate efficacy in IS. There are so many positives that lie ahead, like WST said in his article, Athersys is "firing on all cylinders in 2016", and we already know that 2017-2018 should be off the charts, provided these trial readouts continue to demonstrate efficacy. Like Jason Kolbert said, when MultiStem is unlocked, "it will become a very,very big product."
Sentiment: Strong Buy
And this further supports the inviolate safety profile, more data, more safety, we have a cumulative effect across the stem cell sector, and with MultiStem.
I bought shares based on what was being sold to us as a very fast track pivotal trial and now we know what that looks like when they come back around the corner. When I look at the break in the charts and the delays out front, I sold all my shares for a loss because I know how this trades given time to bleed. Feels like betrayal to me.
I'll toast to your projection VA, it's been so far an exercise in frustration seeing this stock behave like a yoyo since January.
Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders
NEW YORK, NY – June 6, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT.
Fragile X syndrome is the most common form of inherited intellectual disability and the most frequent single gene cause of autism.
“The ANAVEX 2-73 data in an array of behavioral paradigms in a validated mouse model of Fragile X is very encouraging. The results are promising for both Fragile X syndrome and Autism Spectrum Disorders, since there is an overlap in the clinical as well as in the underlying molecular pathology of the two disorders. We would be very interested in continuing the work with ANAVEX 2-73,” said Michael Tranfaglia, MD, Medical Director, Chief Scientific Officer of FRAXA Research Foundation.
Dosing of ANAVEX 2-73 for 14 days in a Fragile X syndrome mouse model was followed by a battery of behavioral tests that are linked to pathophysiological signs of Autism-related disorders and Fragile X syndrome: hyper-locomotion, associative learning, and marble burying. Treatment with ANAVEX 2-73 significantly improved all behaviors tested. ANAVEX 2-73 significantly reversed the hyperactivity and impairment in learning and memory (p≤0.0001), to the same levels observed in vehicle-treated wild-type mice. ANAVEX 2-73 also yielded a partial effect in the mar
Yes, exactly that, and there are a lot of new shareholders, people who have come here and paid up for their shares, only to see the share price get cut and cut again. Some of the recent selling occurred due to people thinking KB was possibly going to leave the Company due to shareholders lawsuits, after he had slayed Goliath. I've talked to KB and he won't comment on this subject, only to say he disrepects message board lies, tactics, and rumors. The last week or so, we look like we are carving out a bottom. Make it so, and let's get this show on the road.
Good comments. Last November 6th, the AVXL 250 dma was about $2.60 whereas today it is 5.49. We were so overbought then as compared to now, with the Company having moved its pipeline so massively forward, on the cusp of 31 week data, there is a so much more reason in place now for massive market cap expansion and holding that, than last November. Any drop should be supported in the least by our 250-dma, but $7.00 going forward looks like it will become support until we re-establish new base camps at higher elevations.
There were fill delays today even at the bid, what a lousy market maker. I did buy some shares, but when is this drop going to end?
Good post Kack. I've talked to KB 3 times, once yesterday and am very comfortable with where we're headed, just hard to give a timetable to it. He knows what needs to be done to drive the value, just let the man execute, he's never sold any shares, he's got more to lose than any of us!
I must admit was very upset to see this stock behaving poorly and as pinstripe's posts surfaced on annual meeting, with mention of data readout in Q1 2018, that's where I had a disconnect between what Gil and Hardy had been saying in their R&D Partnership day video, and subsequent interviews and so forth. They clearly were overselling the Japan PMDA program's fast track aspects. As a result, I lost some serious money here, believing in them. One should come to the table with at least two years for any such investment, so I built too large of a position too fast with average price of 2.28 and chose not to risk the fluctuation which was only beginning. I sold at 2.01-2.04 and won't be trusting Gil and Company anymore.
Athersys's Senior Vice Pres Finance just picked up 57,674 shares - June 21, 2016
Athersys's Exec Vice Pres and CSO just picked up 131,593 shares - June 21, 2016
Athersys's President and COO just picked up 114,097 shares - June 21, 2016
Athersys's Chairman and CEO just picked up 202,253 shares - June 21, 2016
Athersys director was just granted 30,000 options - June 21, 2016
Seven more days in a row of 13% gains and we'll be back to 61 cents. That's how far down we've come in the last two months, during the most accomplished time in the last five years, we dropped 60% in 6 weeks. Who said the stock market is rational? Pure manipulation.
I'm well beyond the point of "just the return of my investment" and I'd go home happy. Not adding just holding and also went back to work. Very tough market, this (if I were to sell now) would be my highest percentage loss ever. I had three chances to take 15% gains and yet it was fleeting each time. We all saw those chances. Biospec smartly took his exit.
What is it about your posting that attracts so many red thumbs? You are an optimist and maybe people think you pump too much. Shorts don't care what we post, maybe I'm wrong?
A verdict in favor of Decn would be sealed and the Company would finance their expansion into world markets without diluting shareholders. Letting the cash go back to shareholders would be stupid, small cap bios struggle to have enough operating funds to attain profitability. This would be the windfall money bridging them to sustained profitability. Go KB, whack those SOB's!
I give Gil credit due for his hhaving accomplished the two Japanese partnerships in Japan, where they are committed to having world firsts in regenerative medicine. Sanbio may have a unique approach but Athersys will be approved in Japan for IS long before Sanbio could get a US approval. MultiStem has blockbuster potential, quickly coming into focus.
Sentiment: Strong Buy